Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Systematic review comparing allogeneic transplant patients with non-transplant patients in MF

Jan Philipp Bewersdorf, MD, Yale School of Medicine, New Haven, CT, discusses the findings of a systematic review evaluating the effect of allogeneic transplant in patients with myelofibrosis (MF). Currently, the only disease-modifying treatment for MF is allogeneic transplant. However, high rate of graft failure and poor performance status of older patients are obstacles to this treatment. Dr Bewersdorf outlines the findings of this investigation and highlights a long-term survival benefit observed in MF patients who opt for transplant over non-transplant patients who are instead treated with JAK inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.